Financial News · Live Terminal

Page 230 of 307

Research61d ago

Guggenheim Initiates Satellos Bioscience at Buy With CA$31.43 Price Target

$MSLE

Research61d ago

BNP Paribas Initiates Coverage on Versigent PLC With Outperform Rating, $41 Price Target

$VGNT

Research61d ago

Guggenheim Initiates Neurogene at Buy With $69 Price Target

Neurogene (NGNE) has an average rating of buy and mean price target of $76.43, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$NGNE

Research61d ago

Research Alert: Zbh Q1 Tops Estimates, Fueled By Diversified Portfolio And Strategic Growth

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Zimmer Biomet delivered solid Q1 2026 results with net sales of $2.087B (+9.3% reported, +2.9% organic constant currency), $20M above the consensus view, and adjusted EPS of $2.09 (+15.5% Y/Y), beating the consensus by $0.23. Performance was broad-based across U.S. markets at $1.209B (+3.2% Y/Y organic) and international operations at $877.4M (+2.5% Y/Y organic). The diversified portfolio enabled resilient performance with knees at $828.6M (+1.8% organic), hips at $524.1M (+3.2% organic), and S.E.T. serving as a growth engine with sales at $562.2M, benefiting from the Paragon 28 acquisition. Management raised full-year EPS guidance to $8.40-$8.55 from $8.30-$8.45 while maintaining revenue guidance of 2.5%-4.5% reported growth. Key milestones in Q1 included mBos robotic system enrollment completion in India, first G7 Acetabular System case following FDA clearance, and Dr. Vigdorchik's appointment as Chief Science Officer.

$ZBH

Research61d ago

TD Cowen Upgrades TELUS to Buy From Hold

$TU

Research61d ago

TD Cowen Initiates Immatics at Buy

Immatics (IMTX) has an average rating of buy and mean price target of $18.68, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$IMTX

Research61d ago

UBS Initiates Coverage on Ultrapar Participacoes With Buy Rating, $7 Price Target

Ultrapar Participacoes (UGP) has an average rating of overweight and mean price target of $5.98, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$UGP

Research61d ago

HC Wainwright Initiates First Tracks Biotherapeutics at Buy

First Tracks Biotherapeutics (TRAX) has an average rating of buy and mean price target of $37, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TRAX

Research61d ago

Piper Sandler Upgrades Organon to Neutral From Underweight, Adjusts Price Target to $14 From $5

Organon (OGN) has an average rating of Underweight and mean price target of $11.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$OGN

Research61d ago

Raymond James Initiates Carlisle at Outperform With $425 Price Target

Carlisle (CSL) has an average rating of overweight and mean price target of $409.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CSL

Research61d ago

William Blair Initiates Cencora at Market Perform

Cencora (COR) has an average rating of overweight and mean price target of $405.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$COR

Research61d ago

Morgan Stanley Upgrades Equinor ASA to Equal Weight From Underweight, Adjusts PT to $40.40 From $22.80

Equinor ASA (EQNR) has an average rating of Underweight and mean price target of $350.58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$EQNR

Research61d ago

William Blair Initiates Cardinal Health at Outperform

Cardinal Health (CAH) has an average rating of overweight and mean price target of $250.93, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CAH

Research61d ago

DA Davidson Initiates Micron Technology at Buy With $1,000 Price Target

Micron Technology (MU) has an average rating of buy and mean price target of $559.21, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$MU

Research61d ago

William Blair Initiates McKesson at Outperform

McKesson (MCK) has an average rating of overweight and mean price target of $997.53, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$MCK

Research61d ago

Research Alert: Epd: Permian Growth Remains Strong, But A Slight Miss In Q1

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Enterprise Products Partners (EPD) kicked off 2026 with Q1 earnings per unit of $0.68, missing consensus by $0.05, though adjusted EBITDA of $2.7B rose 10% Y/Y, reflecting strong underlying performance. Volume growth remained robust across key segments, with record natural gas processing inlet volumes of 8.3 bcf/d up 7% Y/Y and NGL pipeline volumes of 4.9 mmb/d up 10% Y/Y. Growth opportunities in natural gas processing look healthy, with plans for two additional processing plants in 2027 to increase total capacity by 12% and capture growing Permian production. Management noted natural gas and NGL production growth is expected to be 1.6x that of crude oil production growth. The company sees 2026 growth capex of $2.3B-$2.6B, down from original plans of $2.5B-$2.9B. With recent projects in service, we see EPD entering "harvesting mode" with meaningful free cash flow expansion ahead. We think demand for midstream services is increasingly fueled by data center expansion requiring more natural gas pipeline capacity.

$EPD

Research61d ago

Compass Point Initiates American Homes 4 Rent at Buy With $37.50 Price Target

American Homes 4 Rent (AMH) has an average rating of overweight and mean price target of $34.62, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AMH

Research61d ago

Deutsche Bank Initiates Coverage on Versigent With Buy Rating, $35 Price Target

$VGNT

Research61d ago

RBC Raises Price Target on Casey's General Stores to $792 From $713, Keeps Sector Perform Rating

Casey's General Stores (CASY) has an average rating of overweight and mean price target of $753 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$CASY

Research61d ago

Research Alert: CFRA Reiterates Buy View On Shares Of Dover Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Following encouraging Q1 results, we lift our 12-month target to $260 from $250 and reaffirm our Buy view on shares. Our target values shares at 22.4x our 2027 EPS view of $11.62 (up from $11.34; 2026 EPS view is raised to $10.62 from $10.52), near peers' and DOV's historical average multiple. DOV posted operating EPS of $2.28, up 11% Y/Y, as revenue growth accelerated to 10% Y/Y (5% organic), reflecting broad-based strength across the portfolio and momentum in secular growth markets. Clean Energy & Fueling and Climate & Sustainability Technologies led top-line growth with 13% and 18% Y/Y revenue increases, respectively, benefiting from demand in energy transition markets. Bookings performance was sound, with $2.5B in orders (up 24% Y/Y). Notably, management quantified the opportunity from the AI investment supercycle, guiding for $1 billion of related sales to be generated in 2026. DOV is making targeted investments in capacity to meet accelerating demand, with order conversions likely picking up into 2027.

$DOV

Showing 4581-4600 of 6129